Empire Genomics Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
19
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
7
- Investments
-
1
Empire Genomics General Information
Description
Developer of a molecular and cytogenetic diagnostic platform designed to offer a comprehensive menu of assay services for use in diagnosing and guiding precise therapeutic treatments for patients. The company's platform assists in advancing biomarker research, accelerating diagnoses and improving personalized treatment options for patients battling cancer and other complex diseases, enabling healthcare providers to diagnose and guide precise therapeutic treatments for their patients.
Contact Information
Website
www.empiregenomics.com(Operating Subsidiary)
Corporate Office
- 3370 Walden Avenue
- Suite 114
- Depew, NY 14221
- United States
Corporate Office
- 3370 Walden Avenue
- Suite 114
- Depew, NY 14221
- United States
Empire Genomics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Empire Genomics Comparisons
Industry
Financing
Details
Empire Genomics Competitors (41)
One of Empire Genomics’s 41 competitors is OmeCare, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| OmeCare | Formerly VC-backed | San Diego, CA | ||||
| Foundation Medicine | Formerly VC-backed | Boston, MA | ||||
| Agendia | Venture Capital-Backed | Irvine, CA | ||||
| Igenomix USA | Formerly PE-Backed | Paterna, Spain | ||||
| Asuragen | Formerly VC-backed | Austin, TX |
Empire Genomics Patents
Empire Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20090186775-A1 | Method and device for dual array hybridization karyotype analysis | Inactive | 15-Jan-2008 | ||
| WO-2009091535-A1 | Method and device for dual array hybridization karyotype analysis | Inactive | 15-Jan-2008 |
Empire Genomics Signals
Empire Genomics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Empire Genomics Acquisitions (1)
Empire Genomics’s most recent deal was a Merger/Acquisition with ID Labs Biotechnology. The deal was made on 05-Jan-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ID Labs Biotechnology | 05-Jan-2014 | Merger/Acquisition | Other Devices and Supplies |
Empire Genomics FAQs
-
When was Empire Genomics founded?
Empire Genomics was founded in 2006.
-
Where is Empire Genomics headquartered?
Empire Genomics is headquartered in Depew, NY.
-
What is the size of Empire Genomics?
Empire Genomics has 19 total employees.
-
What industry is Empire Genomics in?
Empire Genomics’s primary industry is Business/Productivity Software.
-
Is Empire Genomics a private or public company?
Empire Genomics is a Private company.
-
What is Empire Genomics’s current revenue?
The current revenue for Empire Genomics is .
-
How much funding has Empire Genomics raised over time?
Empire Genomics has raised $4.15M.
-
Who are Empire Genomics’s investors?
BDC Capital, Current Yield with Participation Fund, Rand Capital Corp BDC, SCP Partners, and Z80 have invested in Empire Genomics.
-
Who are Empire Genomics’s competitors?
OmeCare, Foundation Medicine, Agendia, Igenomix USA, and Asuragen are some of the 41 competitors of Empire Genomics.
-
When was Empire Genomics acquired?
Empire Genomics was acquired on 22-Nov-2022.
-
Who acquired Empire Genomics?
Empire Genomics was acquired by Biocare Medical (Discovery Tools).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process